If you're like most individual investors, your brokerage doesn't allow you to buy less than one whole share of a stock at a time. For those of you with brokerages that do allow fractional share ownership, the basket of eligible stocks doesn't always contain the ones you're most interested in at the moment.

Luckily, there are a handful of top stocks in the relatively reliable healthcare sector that you can still scoop up for $100 or less. Read on to see why these inexpensive stocks probably won't be trading so cheaply for much longer.

Three people looking at laptop.

Image source: Getty Images.


Doximity's (DOCS 0.88%) stock price has soared around 89% since the company made its stock market debut this June, and lately it's been hovering around $100 per share. That works out to more than 170 times this year's expected earnings before interest, taxes, depreciation, and amortization (EBITDA).

Doximity is a highly curated social network for licensed medical professionals, and it already claims 80% of U.S. physicians as members. Doctors are drawn to the network by a free dialer app that makes direct voice and video calls to patients. The service is extra popular because it allows doctors to make encrypted calls straight to patients' phone numbers without asking patients to install anything.

Doximity isn't a direct competitor to Teladoc Health, but its dialer app effectively makes the company a leading provider of telehealth services. With heaps of high-margin advertisement revenue to lean on, Doximity can afford to keep bringing in new clinicians by offering its free dialer. 

Chart comparing quarterly operating income of Doximity and Teladoc.

DOCS Operating Income (Quarterly) data by YCharts

In fact, it looks like serving advertising to a social network of medical professionals is a lot more lucrative than Teladoc Health's business model. Teladoc's operation was just approaching profitability when it splashed out on Livongo to differentiate itself from a slew of new telehealth services. Doximity's profitable right out of the box, and there really aren't any competitors in this specialized niche.

Fulgent Genetics

Fulgent Genetics' (FLGT -1.55%) stock price has fallen to around $86 after peaking above $180 in February, largely because of uncertainty regarding COVID-19 testing revenue. After the company's most recent earnings call, it seems like there wasn't much to worry about.

Core revenue soared 296% year over year to $26 million in the second quarter. The acquisition of CSI Laboratories and rising demand for the company's next-generation sequencing services should be sufficient to offset unpredictable COVID-19 testing demand.

This year, Fulgent Genetics expects a revenue contraction, but a strong return to growth is probably up around the next corner. Demand for genetic testing of cancerous tumors is large and growing fast. Demand for genetic testing that can find signs of the disease before it has a chance to get aggressive is even larger. Thanks to the acquisition of CSI Laboratories in August, Fulgent Genetics can do both.

Smiling physician with a patient.

Image source: Getty Images.

Inari Medical

Inari Medical (NARI -1.31%) markets venous clot removal devices that saw a lot of demand from severely ill COVID-19 patients. Shares of Inari Medical peaked above $127 this March. Since then it's tumbled to around $80 per share, thanks to poor communication regarding the strong effect of COVID-19 on demand for deep-vein clot removal.  

Fluctuating COVID revenue that likely isn't coming back thanks to new vaccination mandates probably won't stop Inari Medical from reporting significant growth in 2021. This May, the U.S. Food and Drug Administration (FDA) granted clearance to the company's FlowTriever system for the treatment of pulmonary embolism (PE).

In the U.S., patients with acute PE are generally given powerful blood-thinning agents. Then hospitals need to keep them for long periods of observation while everyone hopes for the best. FlowTreiver involves a non-invasive procedure that removes the clot so patients can quickly get back on their feet and out of the hospital.

Altogether, PE is the third most common reason patients die in U.S. hospitals, with at least 650,000 cases occurring annually. As the only available clot removal device for PE, FlowTreiver sales could explode higher, along with Inari Medical's stock price.